Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Effect of 17% ethylenediaminetetraacetic acid and 0.2% chitosan on pushout bond strength of biodentine and ProRoot mineral trioxide aggregate: An in vitro study.

Prasanthi P, Garlapati R, Nagesh B, Sujana V, Kiran Naik KM, Yamini B.

J Conserv Dent. 2019 Jul-Aug;22(4):387-390. doi: 10.4103/JCD.JCD_56_19.

2.

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.

Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, Buck JY, Demars N, Barrett JA, Gelb AB, Zhou J, Lebel F, Cooper LJN.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaaw5680. doi: 10.1126/scitranslmed.aaw5680.

PMID:
31413142
3.

Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.

Voce DJ, Bernal GM, Wu L, Crawley CD, Zhang W, Mansour NM, Cahill KE, Szymura SJ, Uppal A, Raleigh DR, Spretz R, Nunez L, Larsen G, Khodarev NN, Weichselbaum RR, Yamini B.

Cancer Res. 2019 May 15;79(10):2536-2548. doi: 10.1158/0008-5472.CAN-18-2170. Epub 2019 Apr 2.

PMID:
30940658
4.

Primary Sellar Paraganglioma: Case Report with Literature Review and Immunohistochemistry Resource.

Lyne SB, Polster SP, Fidai S, Pytel P, Yamini B.

World Neurosurg. 2019 May;125:32-36. doi: 10.1016/j.wneu.2019.01.094. Epub 2019 Jan 29. Review.

PMID:
30703592
5.

NF-κB, Mesenchymal Differentiation and Glioblastoma.

Yamini B.

Cells. 2018 Aug 31;7(9). pii: E125. doi: 10.3390/cells7090125. Review.

6.

Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.

Hussain F, Horbinski CM, Chmura SJ, Yamini B, Lukas RV.

Neurologist. 2018 Sep;23(5):163-166. doi: 10.1097/NRL.0000000000000194.

PMID:
30169370
7.

BCL3 expression promotes resistance to alkylating chemotherapy in gliomas.

Wu L, Bernal GM, Cahill KE, Pytel P, Fitzpatrick CA, Mashek H, Weichselbaum RR, Yamini B.

Sci Transl Med. 2018 Jul 4;10(448). pii: eaar2238. doi: 10.1126/scitranslmed.aar2238.

8.

Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.

Young JS, Bernal G, Polster SP, Nunez L, Larsen GF, Mansour N, Podell M, Yamini B.

World Neurosurg. 2018 Sep;117:e698-e704. doi: 10.1016/j.wneu.2018.06.114. Epub 2018 Jun 27.

9.

Intracranial hemorrhage as initial manifestation of plasma cell myeloma: A case report.

Hobbs JG, Van Slambrouck C, Miller JL, Yamini B.

J Clin Neurosci. 2018 Apr;50:133-135. doi: 10.1016/j.jocn.2018.01.054. Epub 2018 Feb 7.

PMID:
29428262
10.

Management of glioblastoma in elderly patients.

Young JS, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas RV.

J Neurol Sci. 2017 Sep 15;380:250-255. doi: 10.1016/j.jns.2017.07.048. Epub 2017 Aug 1. Review.

PMID:
28870580
11.

Evaluating the Cavus Foot.

Eleswarapu AS, Yamini B, Bielski RJ.

Pediatr Ann. 2016 Jun 1;45(6):e218-22. doi: 10.3928/00904481-20160426-01. Review.

PMID:
27294497
12.

Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy.

Cahill KE, Morshed RA, Yamini B.

Neuro Oncol. 2016 Mar;18(3):329-39. doi: 10.1093/neuonc/nov265. Epub 2015 Nov 2. Review.

13.

Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.

Mansour NM, Bernal GM, Wu L, Crawley CD, Cahill KE, Voce DJ, Balyasnikova IV, Zhang W, Spretz R, Nunez L, Larsen GF, Weichselbaum RR, Yamini B.

Cancer Res. 2015 May 15;75(10):2039-48. doi: 10.1158/0008-5472.CAN-14-2144. Epub 2015 Mar 25.

14.

Nfkb1/p50 and mammalian aging.

Yamini B.

Oncotarget. 2015 Feb 28;6(6):3471-2. No abstract available.

15.

S-phase-dependent p50/NF-кB1 phosphorylation in response to ATR and replication stress acts to maintain genomic stability.

Crawley CD, Kang S, Bernal GM, Wahlstrom JS, Voce DJ, Cahill KE, Garofalo A, Raleigh DR, Weichselbaum RR, Yamini B.

Cell Cycle. 2015;14(4):566-76. doi: 10.4161/15384101.2014.991166.

16.

Loss of Nfkb1 leads to early onset aging.

Bernal GM, Wahlstrom JS, Crawley CD, Cahill KE, Pytel P, Liang H, Kang S, Weichselbaum RR, Yamini B.

Aging (Albany NY). 2014 Nov;6(11):931-43.

17.

Nfkb1 suppresses DNA alkylation-induced tumor formation.

Schmitt AM, Yamini B.

Mol Cell Oncol. 2015 Jan 28;2(1):e968073. doi: 10.4161/23723548.2014.968073. eCollection 2015 Jan-Mar.

18.

Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor.

Voce DJ, Schmitt AM, Uppal A, McNerney ME, Bernal GM, Cahill KE, Wahlstrom JS, Nassiri A, Yu X, Crawley CD, White KP, Onel K, Weichselbaum RR, Yamini B.

Oncogene. 2015 May 21;34(21):2807-13. doi: 10.1038/onc.2014.211. Epub 2014 Jul 21.

19.

Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.

Bernal GM, LaRiviere MJ, Mansour N, Pytel P, Cahill KE, Voce DJ, Kang S, Spretz R, Welp U, Noriega SE, Nunez L, Larsen GF, Weichselbaum RR, Yamini B.

Nanomedicine. 2014 Jan;10(1):149-57. doi: 10.1016/j.nano.2013.07.003. Epub 2013 Jul 24.

20.

DNA damage-induced cytotoxicity is mediated by the cooperative interaction of phospho-NF-κB p50 and a single nucleotide in the κB-site.

Crawley CD, Raleigh DR, Kang S, Voce DJ, Schmitt AM, Weichselbaum RR, Yamini B.

Nucleic Acids Res. 2013 Jan;41(2):764-74. doi: 10.1093/nar/gks1120. Epub 2012 Nov 24.

Supplemental Content

Loading ...
Support Center